A new antiviral drug that induces mutations in the genetic material of influenza virus is highly effective in treating influenza infection in animals and human airway tissue and could be a groundbreaking advance in influenza therapy, according to a study by the Institute for Biomedical Sciences at Georgia State University.
The antiviral drug blocks RNA polymerase, the enzyme that plays a central role in replicating the genome of influenza virus, causing mutations in the viral genome. If enough mutations occur, the genome becomes nonfunctional and the virus cannot replicate. The findings were published online on Oct. 23 in Science Translational Medicine.
“The compound is highly efficacious against influenza,” said Dr. Richard Plemper, senior author of the study and a professor in the Institute for Biomedical Sciences. “It’s orally available, it’s broad spectrum against all influenza virus strains tested, and most important it establishes a high barrier against viral escape from inhibition.”
Influenza, caused by a contagious respiratory virus, is characterized by fever, cough, headache, muscle and joint pain, severe malaise, sore throat and sometimes gastrointestinal symptoms. Patients in higher risk groups, such as older adults and individuals with compromised immune systems, frequently require hospitalization. Each year, seasonal influenza results in 30,000 to 80,000 fatalities in the United States. The seasonal flu vaccine is only moderately effective, and licensed antivirals are compromised by rapidly emerging viral resistance to the drugs.
In the study, the new antiviral drug was tested in ferrets, the most informative animal model for human influenza disease, against various strains that include seasonal and pandemic viruses, such as the swine-origin influenza virus responsible for a 2009 pandemic. The researchers found that the antiviral drug efficiently inhibited replication of all of these strains. Virus burden dropped rapidly after treatment, and the duration of fever was significantly shorter in treated ferrets than in control animals that did not receive the drug.
“We think that the next generation of influenza antiviral drugs must not only be efficacious and safe, but also address the resistance problem,” said Dr. Mart Toots, first author of the study and a research assistant professor associated with Dr. Plemper’s lab in the Institute for Biomedical Sciences.
That is where the new drug comes in. Through a combination of conventional and ultra-deep sequencing, Toots has demonstrated in collaboration with Dr. Alex Greninger at the University of Washington that it is very challenging for the virus to find a viable way to avoid the compound.
“We have not identified specific resistance mutations yet and are confident to say that the genetic barrier against viral resistance is high,” Plemper said. “We believe that this compound has high clinical potential as a next-generation influenza drug that combines key antiviral features.”
The Latest on: Influenza
via Google News
The Latest on: Influenza
- The Worldwide Influenza Diagnostics Industry is Expected to Reach $1.1 Billion by 2026 - ResearchAndMarkets.comon October 11, 2021 at 9:02 am
Test Type (Traditional (RIDT, Viral Culture, Serological), Molecular (PCR, INAAT- NASBAT, TMABAS), End User (Diagnostic Laboratories, Hospitals, Clinics), Region-Global Forecast to 2026" report has ...
- U.S. Influenza Diagnostics Market Research Analysis, and Future Innovations | Grand View Research, Inc.on October 11, 2021 at 7:05 am
According to a new report published by Grand View Research, influenza is a contagious disease therefore, there is an easy transmission of the disease ...
- Prior immunity to influenza, not SARS-CoV-2, prevents severe disease and mortalityon October 11, 2021 at 3:07 am
Researchers from the Israel Institute of Biological Research delineated the interplay between IAV and SARS CoV-2 infections.
- Health officials warn of ‘triple threat’ this fall: RSV, influenza and COVID-19on October 10, 2021 at 7:07 pm
Once again, flu season is upon us. Each year, it can vary, but usually lasts from October through May. This fall, it’s especially important to get vaccinated since flu is not the only ...
- Severe influenza outbreak expected in the United States after relaxation of COVID control measureson October 9, 2021 at 8:02 pm
New research warns that the United States could experience a severe influenza outbreak after public health measures like face masks and social distancing are lifted.
- COVID Or Flu? New Test Can Detect Both Coronavirus And Influenza Viruson October 8, 2021 at 9:11 pm
With similar symptoms like fever, tiredness, cough, and shortness of breath... doctors around the Denver metro area will have another tool to determine if patients are sick with COVID-19 or influenza.
- Influenza hemagglutinin attachment to target cells: ‘birds do it, we do it…’on October 8, 2021 at 5:56 pm
Influenza A viruses have been much in the news lately, and rightly so. This divergent group of viruses has caused occasional and unpredictable pandemics, some with horrific consequences, and also ...
- “The 1918 Influenza Epidemic Was a Vaccine – Caused Disease.”on October 7, 2021 at 6:31 pm
Spanish Flu Pandemic Which Vaccine Killed 20 Million People? “The 1918 Influenza Epidemic Was a Vaccine – Caused Disease.” Very few people realize that the worst epidemic ever to hit America, the ...
- US Health Officials Urge Vaccination Amid Concerns About Influenza Resurgence During Ongoing Pandemicon October 7, 2021 at 6:57 am
"While we do not know what flu activity will be like this fall—I urge everyone age 6 months and older to get vaccinated. If you are unsure about getting a flu vaccine, please take the time to get the ...
- Don't forget about the return of influenzaon October 6, 2021 at 10:32 pm
COVID-19 has been the hot topic for the past year and a half, monopolizing TV news programs and documentaries. However, we cannot forget about the infectious disease that returns every ...
via Bing News